Literature DB >> 15531403

NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.

Robert S Kern1, Michael F Green, Keith H Nuechterlein, Bi-Hong Deng.   

Abstract

The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative requires, among other things, the establishment of a reliable, valid, and consensus-derived method of assessing cognition. The derived battery will provide a standardized way to assess the effects of cognition-enhancing agents across clinical trials. To this end, the first of six consensus-oriented conferences was held April 2003. The goals were twofold: (a) To select which cognitive constructs to measure in a consensus battery, and (b) to select which criteria to use in evaluating tests for inclusion in the battery. Based on consultation with experts on the RAND Panel Method, 74 experts were invited to participate in a pre-meeting survey to provide information relevant to decisions on the cognitive battery. The survey included sections on reliability, validity, test administration, norms and interpretation of tests, cognitive domains and their integration, battery duration, and overall importance of test qualities. For selection of cognitive targets, the results showed that experts ranked executive functions, attention/vigilance, memory processes, and problem-solving ability highest. For test qualities, the experts ranked test-retest reliability, good coverage of key individual cognitive constructs, and comparable alternate forms highest. This article presents the results of the pre-conference survey that was the first step in the RAND process towards development of the NIMH-MATRICS consensus battery to assess cognition in schizophrenia.

Entities:  

Mesh:

Year:  2004        PMID: 15531403     DOI: 10.1016/j.schres.2004.09.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  35 in total

1.  Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia.

Authors:  Dwight Dickinson; James M Gold
Journal:  Schizophr Bull       Date:  2007-08-16       Impact factor: 9.306

Review 2.  Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.

Authors:  Richard S E Keefe; Philip D Harvey
Journal:  Schizophr Bull       Date:  2008-05-20       Impact factor: 9.306

3.  A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses.

Authors:  Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer
Journal:  Schizophr Res       Date:  2019-01-31       Impact factor: 4.939

4.  COMT and anxiety and cognition in children with chromosome 22q11.2 deletion syndrome.

Authors:  Vandana Shashi; Timothy D Howard; Matcheri S Keshavan; Jessica Kaczorowski; Margaret N Berry; Kelly Schoch; Edward J Spence; Thomas R Kwapil
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

5.  Integrated psychological therapy (IPT) for schizophrenia: is it effective?

Authors:  Volker Roder; Daniel R Mueller; Kim T Mueser; Hans D Brenner
Journal:  Schizophr Bull       Date:  2006-08-17       Impact factor: 9.306

6.  Socioeconomic status and psychological function in children with chromosome 22q11.2 deletion syndrome: implications for genetic counseling.

Authors:  Vandana Shashi; Matcheri Keshavan; Jessica Kaczorowski; Kelly Schoch; Kathryn E Lewandowski; Allyn McConkie-Rosell; Stephen R Hooper; Thomas R Kwapil
Journal:  J Genet Couns       Date:  2010-08-03       Impact factor: 2.537

7.  Working memory span capacity improved by a D2 but not D1 receptor family agonist.

Authors:  Isadore S Tarantino; Richard F Sharp; Mark A Geyer; Jessica M Meves; Jared W Young
Journal:  Behav Brain Res       Date:  2011-01-11       Impact factor: 3.332

8.  Evidence of gray matter reduction and dysfunction in chromosome 22q11.2 deletion syndrome.

Authors:  Vandana Shashi; Thomas R Kwapil; Jessica Kaczorowski; Margaret N Berry; Cesar S Santos; Timothy D Howard; Dhruman Goradia; Konasale Prasad; Diwadkar Vaibhav; Rajaprabhakaran Rajarethinam; Edward Spence; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2010-01-30       Impact factor: 3.222

9.  Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

Authors:  S Kristian Hill; John A Sweeney; Robert M Hamer; Richard S E Keefe; Diana O Perkins; Hongbin Gu; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

10.  Performance-based empathy mediates the influence of working memory on social competence in schizophrenia.

Authors:  Matthew J Smith; William P Horan; Derin J Cobia; Tatiana M Karpouzian; Jaclyn M Fox; James L Reilly; Hans C Breiter
Journal:  Schizophr Bull       Date:  2013-06-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.